The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys

Journal of Thrombosis and Thrombolysis

Volumn 41, Issue 3, 2016, Pages 514-521

  Wong, Pancras C ^a   Watson, Carol ^a   Crain, Earl J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Abciximab; Antiplatelet; Cangrelor; Hemostasis; MRS2500; Nonhuman primates; Thrombosis

Indexed keywords

4 (2 IODO 6 METHYLAMINO 9H PURIN 9 YL) 2 PHOSPHONOOXYBICYCLO[3.1.0]HEXANE 1 METHANOL; ABCIXIMAB; ARACHIDONIC ACID; CANGRELOR; PURINERGIC P2Y1 RECEPTOR; 2-IODO-N(6)-METHYL-(N)-METHANOCARBA-2'-DEOXYADENOSINE-3',5'-BISPHOSPHATE; DEOXYADENOSINE PHOSPHATE; PURINERGIC P2Y RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERY BLOOD FLOW; ARTICLE; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FIBRIN FORMATION; HEMOSTASIS; KIDNEY BLEEDING TIME; KIDNEY HEMORRHAGE; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE AGGREGATION; THROMBUS; THROMBUS WEIGHT; ANIMAL; CAROTID ARTERY; PRECLINICAL STUDY; THROMBOSIS;

ANIMALS; CAROTID ARTERIES; DEOXYADENINE NUCLEOTIDES; DRUG EVALUATION, PRECLINICAL; MACACA FASCICULARIS; PURINERGIC P2Y RECEPTOR AGONISTS; THROMBOSIS;

EID: 84949643316     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1302-7     Document Type: Article

References (22)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O’Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2006) Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:85–151
2. Wiviott SD, Steg PG (2015) Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet 386:292–302
3. Gachet C (2015) Antiplatelet drugs: which targets for which treatments? J Thromb Haemost 13(Suppl 1):S313–S322
4. Hechler B, Gachet C (2011) P2 receptors and platelet function. Purinergic Signal 7:293–303
5. Keating GM (2015) Cangrelor: a review in percutaneous coronary intervention drugs. Drugs 75:1425–1434
6. 1 receptor. Arterioscler Thromb Vasc Biol 35:637–644
7. 1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther 316:556–563
8. 1 deletion or antagonism protects mice from vena cava thrombosis. J Thromb Thrombolysis 34:199–207
9. 1 antagonists as novel antiplatelet agents. J Med Chem 57:6150–6164
10. Ibbotson T, McGavin JK, Goa KL (2003) Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 63:1121–1163
11. Wong PC, Crain EJ, Knabb RM, Meade RP, Quan ML, Watson CA, Wexler RR, Wright MR, Slee AM (2002) Nonpeptide factor Xa inhibitors: II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 295:212–218
12. Schumacher WA, Bostwick JS, Stewart AB, Steinbacher TE, Xin B, Wong PC (2010) Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. J Cardiovasc Pharmacol 55:609–616
13. Das J, Kimball SD, Hall SE, Han WC, Iwanowicz E, Lin J, Moquin RV, Reid JA, Sack JS, Malley MF, Chang CY, Chong S, Wang-Iverson DB, Roberts DG, Seiler SM, Schumacher WA, Ogletree ML (2002) Molecular design and structure–activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664. Bioorg Med Chem Lett 12:45–49
14. Rote WE, Nedelman MA, Mu DX, Manley PJ, Weisman H, Cunningham MR, Lucchesi BR (1994) Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys. Stroke 25:1223–1232
15. Wong PC, Crain EJ, Jiang X, Bostwick JS, Thibeault C, Ruel R, Rehfuss R, Schumacher WA, Ogletree ML (2006) Differential effects of P2Y12 versus P2Y1 antagonism on thrombosis, bleeding and ex vivo platelet aggregation in rabbits. Circulation 114:II_248 abstract 1310
16. Wong PC, Jiang X (2010) Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 104:302–310
17. Fareed J, Bacher P, Messmore HL, Walenga JM, Hoppensteadt DA, Strano A, Pifarre R (1992) Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs. Prog Cardiovas Dis 6:379–398
18. Romson JL, Haack DW, Lucchesi BR (1980) Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 17:841–845
19. Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, Chiariello M, Bach R, Garen A, Konigsberg WK, Ezekowitz MD (1994) A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 74:56–63
20. Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR (2000) Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharmacol Exp Ther 295:492–499
21. Chintala M, Strony J, Yang B, Kurowski S, Li Q (2010) SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 30:2143–2149
22. 1 receptor. Biochem Pharmacol 68:1995–2002